Posted by Michael Wonder on 18 Apr 2017
Janssen receives Health Canada approval of Darzalex (daratumumab) by priority review for patients with multiple myeloma who have had at least one prior therapy
17 April 2017 - Darzalex combination therapy significantly improved progression-free survival compared to standard of care regimens alone.
Janssen announced today that Health Canada has approved Darzalex (daratumumab), in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Due to the high unmet medical need for multiple myeloma patients, Darzalex was granted a priority review by Health Canada for this submission.
